Author: Liu, Hanqing; Yang, Dan; Chen, Xinyue; Sun, Zhihong; Zou, Yutong; Chen, Chuang; Sun, Shengrong
Title: The effect of anticancer treatment on cancer patients with COVIDâ€19: A systematic review and metaâ€analysis Cord-id: qde3nb9z Document date: 2020_12_31
ID: qde3nb9z
Snippet: BACKGROUND: The relationship between cancer and COVIDâ€19 has been revealed during the pandemic. Some anticancer treatments have been reported to have negative influences on COVIDâ€19â€infected patients while other studies did not support this hypothesis. METHODS: A literature search was conducted in WOS, PubMed, Embase, Cochrane Library, CNKI and VIP between Dec 1, 2019 and Sept 23, 2020 for studies on anticancer treatments in patients with COVIDâ€19. Cohort studies involving over 20 patien
Document: BACKGROUND: The relationship between cancer and COVIDâ€19 has been revealed during the pandemic. Some anticancer treatments have been reported to have negative influences on COVIDâ€19â€infected patients while other studies did not support this hypothesis. METHODS: A literature search was conducted in WOS, PubMed, Embase, Cochrane Library, CNKI and VIP between Dec 1, 2019 and Sept 23, 2020 for studies on anticancer treatments in patients with COVIDâ€19. Cohort studies involving over 20 patients with cancer were included. The characteristics of the patients and studies, treatment types, mortality, and other additional outcomes were extracted and pooled for synthesis. RRs and forest plots were adopted to present the results. The literature quality and publication bias were assessed using NOS and Egger's test, respectively. RESULTS: We analyzed the data from 29 studies, with 5121 cancer patients with COVIDâ€19 meeting the inclusion criteria. There were no significant differences in mortality between patients receiving anticancer treatment and those not (RR 1.17, 95%CI: 0.96–1.43, I(2)=66%, p = 0.12). Importantly, in patients with hematological malignancies, chemotherapy could markedly increase the mortality (RR 2.68, 95% CI: 1.90–3.78, I(2)=0%, p < 0.00001). In patients with solid tumors, no significant differences in mortality were observed (RR 1.16, 95% CI: 0.57–2.36, I(2)=72%, p = 0.67). In addition, our analysis revealed that anticancer therapies had no effects on the ICU admission rate (RR 0.87, 95% CI: 0.70–1.09, I(2)=25%, p = 0.23), the severe rate (RR 1.04, 95% CI: 0.95–1.13, I(2)=31%, p = 0.42), or respiratory support rate (RR 0.92, 95% CI: 0.70–1.21, I(2)=32%, p = 0.55) in COVIDâ€19â€infected patients with cancer. Notably, patients receiving surgery had a higher rate of respiratory support than those without any antitumor treatment (RR 1.87, 95%CI: 1.02–3.46, I(2)=0%, p = 0.04). CONCLUSIONS: No significant difference was seen in any anticancer treatments in the solid tumor subgroup. Chemotherapy, however, will lead to higher mortality in patients with hematological malignancies. Multicenter, prospective studies are needed to reâ€evaluate the results.
Search related documents:
Co phrase search for related documents- aberrant inflammatory response and admission rate: 1
- abstract title and acute ards respiratory distress syndrome: 1
- abstract title and low heterogeneity: 1, 2
- acute ards respiratory distress syndrome and additional outcome: 1
- acute ards respiratory distress syndrome and admission bias: 1
- acute ards respiratory distress syndrome and admission date: 1
- acute ards respiratory distress syndrome and admission rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute ards respiratory distress syndrome and low dose radiation: 1, 2
- acute ards respiratory distress syndrome and low heterogeneity: 1, 2, 3
- acute ards respiratory distress syndrome and lymphocyte decrease: 1, 2
- acute ards respiratory distress syndrome and lymphopenia lead: 1
Co phrase search for related documents, hyperlinks ordered by date